江苏澳洋健康产业股份有限公司 江苏澳洋健康产业股份有限公司（以下简称"公司"）于2025年4月11日召 开第九届董事会第三次会议，审议通过了《关于为全资子公司提供反担保的议案》。 因公司全资子公司张家港澳洋医院有限公司（以下简称"澳洋医院"）经营 发展需要，拟向中国光大银行股份有限公司张家港支行（以下简称"光大张家港 支行"）申请综合授信（包括但不限于借款、开立银票、信用证、打包贷款、其 他融资业务其他非融资业务）2,000万元，期限1年。上述授信由张家港市金港投 融资担保有限公司（以下简称"金港投融"）提供连带责任保证担保，并由公司 向金港投融提供全额反担保，期限为履行垫付之日起三年。 关于为全资子公司提供反担保的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 一、 担保情况概述 关于为全资子公司提供反担保的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-14 公司与金港投融之间不存在关联关系，本次反担保不构成关联交易。根据《深 圳证券交易所股票上市规则》及《公司章程》等相关规定，本次反担保事项尚需 提交股东大会审议。 ...

关于召开 2024 年年度股东大会的通知 证券代码：002172 证券简称：澳洋健康 公告编号：2025-18 江苏澳洋健康产业股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏澳洋健康产业股份有限公司（以下简称"公司"）第九届董事会第三次会 议决定于 2025 年 5 月 7 日（星期三）下午 14:00 在张家港市杨舍镇塘市澳洋国 际大厦 A 座会议室召开公司 2024 年年度股东大会，本次股东会议采取现场投票 与网络投票相结合的方式。现将本次会议有关事项通知如下： 一、会议召开的基本情况 1、股东大会届次：2024 年年度股东大会。 2、会议召集人：公司董事会。 3、会议召开的合法合规性说明：董事会召开本次股东大会符合《公司法》 《证券法》《深圳证券交易所股票上市规则》《上市公司股东大会规则》等有关法 律法规、规则以及《公司章程》的规定。 4、会议召开地点：张家港市杨舍镇塘市澳洋国际大厦 A 座会议室。 5、会议召开时间： （1）现场会议时间：2025 年 5 月 7 日（星期三）下午 14:00。 ...

第九届监事会第三次会议决议公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-07 表决结果：同意3票，反对0票，弃权0票。 二、审议通过《2024年度财务决算报告》 该议案尚需提交公司股东大会审议。 表决结果：同意3票，反对0票，弃权0票。 三、审议通过《2024年年度报告》全文及摘要 江苏澳洋健康产业股份有限公司 第九届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏澳洋健康产业股份有限公司（以下简称"本公司"或"公司"）第九届监事 会第三次会议于 2025 年 4 月 1 日以通讯方式发出会议通知，于 2025 年 4 月 11 日上午在公司会议室以现场会议方式召开。会议应出席监事 3 名，实际出席会议 监事 3 名。会议由公司监事会主席顾慎侃先生主持，符合《公司法》及公司《章 程》的有关规定。会议经认真审议，通过如下议案： 一、审议通过《2024年度监事会工作报告》 该议案尚需提交公司股东大会审议。 2024年度报告的编制和审核程序符合法律、行政法规和中国证监会的规定， 报告内容真实、准确、完整地反映了公司 ...

江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）第九 届董事会第三次会议于 2025 年 4 月 1 日以通讯方式发出会议通知，于 2025 年 4 月 11 日上午在公司会议室以现场结合通讯方式召开。会议应出席董事 9 名，实 际出席会议董事 9 名。公司监事及高管列席了会议。会议由公司董事长沈学如先 生主持，符合《公司法》及公司《章程》的有关规定。会议经认真审议，通过如 下议案： 江苏澳洋健康产业股份有限公司 一、审议通过《2024 年度总经理工作报告》 证券代码：002172 证券简称：澳洋健康 公告编号：2025-06 第九届董事会第三次会议决议公告 关联董事李静女士回避表决。 表决结果：同意 8 票，反对 0 票，弃权 0 票。 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，并对公告的 虚假记载、误导性陈述或者重大遗漏负连带责任。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 三、审议通过《2024 年度财务决算报告》 报告期内，公司实现营业总收入 200,977.52 万元，比上年同期减少 7.54%； 实现营业利润 6,760.86 ...

第九届董事会独立董事专门会议第二次会议决议 江苏澳洋健康产业股份有限公司 第九届董事会独立董事专门会议第二次会议决议 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号－主板上市公司规范运作》等相关法 律法规、规范性文件及《公司章程》《独立董事专门会议工作制度》的有关规定， 江苏澳洋健康产业股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开 了公司第九届董事会独立董事专门会议第二次会议，会议应到独立董事 3 名，实 到独立董事 3 名。本次会议的召集、召开和表决程序符合有关法律法规、规范性 文件及《公司章程》的规定。独立董事在认真审阅相关材料的基础上，基于独立 客观的原则，本着对公司及全体股东负责的态度，经各位独立董事审议和表决， 形成以下决议： 一、审议通过了《关于 2024 年度利润分配的预案》 经审议，我们认为，2024 年度利润分配预案充分考虑了公司现阶段的经营状 况、资金需求及未来发展等因素，有利于公司的持续稳定和健康发展，不存在损 害投资者利益的情况，该预案符合公司实际情况。因此，独立董事一致同意该议 案，并提交公司董 ...

2024 年度利润分配预案的公告 江苏澳洋健康产业股份有限公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示 1、截至2024年12月31日，合并报表归属于上市公司股东的未分配利润总额 -1,932,522,582.60元，母公司报表未分配利润总额为-2,053,809,749.41元。公司2024 年度利润分配预案为：不派发现金红利，不送红股，不以公积金转增股本。 2.公司利润分配预案不涉及《深圳证券交易所股票上市规则》第9.8.1条相关规定 的可能被实施其他风险警示情形。 一、审议程序 江苏澳洋健康产业股份有限公司（以下简称"公司"）于2025年4月11日召开的 第九届董事会第三次会议和第九届监事会第三次会议，以同意9票，反对0 票，弃权0票的表决结果审议通过了《2024年度利润分配的预案》。 证券代码：002172 证券简称：澳洋健康 公告编号：2025-09 二、2024年度利润分配预案的基本内容 经立信会计师事务所（特殊普通合伙）出具的信会师报字[2025]第ZA10840号 《审计报告》确认，2024年 ...

澳洋健康（002172）公告，2024年营业收入20.1亿元，同比下降7.54%。归属于上市公司股东的净利润 4056.19万元，同比下降18.36%。基本每股收益0.05元/股，同比下降16.67%。公司计划不派发现金红 利，不送红股，不以公积金转增股本。 ...

澳洋健康（002172）公告，公司决定终止全资子公司增资事项。原计划聚心投资、聚力投资分别增资 3060万元和4850万元，但因市场环境变化，经审慎研究与增资方协商一致终止。该决定已在公司董事会 和监事会审议通过，尚需提交股东大会审议。本次增资事项未开展实质性落实，相关协议未签署且未支 付相应款项，不会对公司生产经营造成重大影响。 ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥2.01 billion, a decrease of 7.54% compared to ¥2.17 billion in 2023[17]. - The net profit attributable to shareholders for 2024 was approximately ¥40.56 million, down 18.36% from ¥49.68 million in 2023[17]. - The net profit after deducting non-recurring gains and losses increased by 19.35% to approximately ¥32.58 million in 2024, compared to ¥27.29 million in 2023[17]. - The basic earnings per share for 2024 was ¥0.05, a decrease of 16.67% from ¥0.06 in 2023[17]. - Total assets at the end of 2024 were approximately ¥2.05 billion, down 8.49% from ¥2.24 billion at the end of 2023[17]. - The weighted average return on equity for 2024 was 35.53%, a decrease of 36.43% from 71.96% in 2023[17]. - The gross margin for medical services was 19.92%, while for pharmaceutical logistics it was 6.73%, indicating a slight decrease in both segments[49]. - The company reported a net loss from investment of ¥1,312,375.05, which constituted -2.01% of total profit[60]. - The company reported a net profit of -15.39 million yuan for 2022, a significant deviation from the initial profit forecast of 5 to 7.5 million yuan[97]. - The company reported a net profit of 900,000, which remains unchanged from the previous year, indicating stability in profitability despite market fluctuations[200]. Cash Flow and Liquidity - The net cash flow from operating activities for 2024 was approximately ¥438.65 thousand, a significant decline of 99.19% from ¥54.30 million in 2023[17]. - The company reported a significant decline in cash flow from operating activities, indicating potential liquidity issues[17]. - Cash flow from operating activities for 2024 was 438,651.63, down from 54,303,048.16 in 2023, showing a decline of approximately 99.2%[193]. - The total cash inflow from financing activities in 2024 was 1,335,831,659.50, compared to 2,001,230,800.48 in 2023, a decrease of about 33.3%[194]. - The net cash flow from financing activities for 2024 was -49,545,729.00, compared to -11,428,440.96 in 2023, indicating a worsening of approximately 334.5%[194]. - The total cash and cash equivalents at the end of 2024 were 266,066,794.14, down from 353,971,272.78 in 2023, a decrease of about 24.6%[194]. - The company's total liabilities decreased, with cash outflow for debt repayment in 2024 at 1,204,074,220.57, down from 1,553,676,455.34 in 2023, a reduction of about 22.5%[196]. Investments and Growth Strategies - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new health technologies and products[95]. - The company plans to expand its market presence and invest in new product development, aiming for a revenue growth target of 10% for the upcoming fiscal year[198]. - The company has initiated a strategic review of potential acquisitions to enhance its competitive position in the market[198]. - The company plans to enhance its medical service network and increase market share in Zhangjiagang, aiming for a more integrated healthcare model[73]. - The company is actively seeking new growth opportunities in the health industry, particularly in functional foods and health supplements[44]. Regulatory and Governance - The company has established a comprehensive governance structure, adhering to regulations and ensuring independent operations from its controlling shareholder[83]. - The company is focusing on improving internal control systems and enhancing corporate governance in response to regulatory feedback[97]. - The company plans to strengthen its information disclosure management to comply with regulatory requirements[97]. - The company has implemented a robust information disclosure and investor relations management system to maintain transparency and communication with stakeholders[81]. - The company has faced scrutiny for its financial reporting practices, highlighting the need for improved accuracy in future disclosures[97]. Market Position and Industry Outlook - The healthcare management industry in China is projected to exceed 1.3 trillion RMB by the end of 2025, with a stable year-on-year growth rate[32]. - The government plans to increase healthcare spending to a new high in 2025, focusing on enhancing grassroots medical service capabilities[29]. - The digitalization of healthcare services is expected to improve resource utilization and patient experience significantly[30]. - The application of artificial intelligence in healthcare is anticipated to enhance diagnostic accuracy and treatment efficiency, particularly in oncology and cardiovascular diseases[31]. Shareholder and Management Information - The annual shareholders meeting had a participation rate of 31.51% on May 17, 2024[84]. - The first extraordinary shareholders meeting had a participation rate of 33.33% on June 24, 2024[84]. - The second extraordinary shareholders meeting had a participation rate of 32.16% on November 25, 2024[84]. - The total shares held by directors and senior management at the end of the reporting period was 613,840 shares[86]. - Director Yuan Yibing resigned as CFO on May 17, 2024, due to personal reasons[86]. - The company has a diverse board with members holding various positions in multiple subsidiaries[87][88][89]. Operational Efficiency - The company has established partnerships with three major healthcare providers to enhance service delivery and expand its market reach[92]. - Jiangsu Aoyang's operational efficiency has improved, with a reduction in operational costs by 5% year-over-year[93]. - The company has identified cost-saving strategies that could reduce operational expenses by 12% in the next fiscal year[144]. Social Responsibility and Community Engagement - The company has actively participated in social responsibility initiatives, including free medical consultations in communities[120].

Group 1 - The core viewpoint of the articles highlights the performance and market position of Aoyang Health, which has a current stock price of 3.27 yuan, reflecting a 2.51% increase, with a rolling PE ratio of 51.38 times and a total market capitalization of 2.504 billion yuan [1][2] - Aoyang Health's main business focuses on health care, including pharmaceutical logistics, medical services, and health care services, with four hospitals established in Zhangjiagang City [1] - The company has received various accolades, including being recognized as a tertiary comprehensive hospital and passing JCI re-evaluation, which enhances its reputation in the health sector [1] Group 2 - For the third quarter of 2024, Aoyang Health reported an operating income of 1.501 billion yuan, a year-on-year decrease of 7.54%, and a net profit of 38.6781 million yuan, down 2.39% year-on-year, with a sales gross margin of 13.72% [2] - In terms of industry comparison, Aoyang Health's PE ratio of 51.38 is higher than the industry average of 46.79 and the industry median of 47.81 [2] - As of September 30, 2024, Aoyang Health had 56,603 shareholders, an increase of 601 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]